Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Staropoli

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Ebiomedicine|October 22, 2021
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective studyBlandine Monel, Delphine Planas, Ludivine Grzelak, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2023
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patientsTimothée Bruel, Lou-Léna Vrignaud, Françoise Porrot, et al.
Med (New York, N.Y.)|October 14, 2023
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patientsTimothée Bruel, Lou-Léna Vrignaud, Françoise Porrot, et al.
Science Advances|August 19, 2021
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infectionNader Yatim, Jeremy Boussier, Pauline Tetu, et al.
Nature|July 8, 2021
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationDelphine Planas, David Veyer, Artem Baidaliuk, et al.
Ebiomedicine|July 1, 2026
Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primatesRomain Marlin, Mireille Centlivre, Laetitia Bossevot, et al.
Nature|January 11, 2022
Considerable escape of SARS-CoV-2 Omicron to antibody neutralizationDelphine Planas, Nell Saunders, Piet Maes, et al.
Nature Medicine|March 27, 2021
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesDelphine Planas, Timothée Bruel, Ludivine Grzelak, et al.
The Journal of Experimental Medicine|June 15, 2022
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Cyril Planchais, Ignacio Fernández, Timothée Bruel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 25, 2022
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell DisordersJulien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Ebiomedicine|October 22, 2021
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective studyBlandine Monel, Delphine Planas, Ludivine Grzelak, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2023
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patientsTimothée Bruel, Lou-Léna Vrignaud, Françoise Porrot, et al.
Med (New York, N.Y.)|October 14, 2023
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patientsTimothée Bruel, Lou-Léna Vrignaud, Françoise Porrot, et al.
Science Advances|August 19, 2021
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infectionNader Yatim, Jeremy Boussier, Pauline Tetu, et al.
Nature|July 8, 2021
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationDelphine Planas, David Veyer, Artem Baidaliuk, et al.
Ebiomedicine|July 1, 2026
Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primatesRomain Marlin, Mireille Centlivre, Laetitia Bossevot, et al.
Nature|January 11, 2022
Considerable escape of SARS-CoV-2 Omicron to antibody neutralizationDelphine Planas, Nell Saunders, Piet Maes, et al.
Nature Medicine|March 27, 2021
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesDelphine Planas, Timothée Bruel, Ludivine Grzelak, et al.
The Journal of Experimental Medicine|June 15, 2022
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Cyril Planchais, Ignacio Fernández, Timothée Bruel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 25, 2022
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell DisordersJulien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, et al.
Pageof 7